W Yoon1, S K Kim, M S Park, H J Chae, H K Kang. 1. Departments of Radiology, Chonnam National University Medical School, Chonnam National University Hospital, Gwangju, Republic of Korea. radyoon@jnu.ac.kr
Abstract
BACKGROUND AND PURPOSE: Carotid IPH can be detected with MR imaging. The aim of this study was to determine the safety of CAS using an emboli protection device in patients with severe carotid artery stenosis and MR imaging-depicted carotid IPH. MATERIALS AND METHODS: We retrospectively reviewed a prospective data base that included 91 consecutive patients with severe carotid stenosis and high-risk features who were treated with CAS by using an emboli protection device. Seventy-eight of the included patients underwent prestenting 3D TOF MRA. IPH was defined as the presence of high signal intensity within the carotid plaque, greater than 150% of the signal intensity of the adjacent neck muscle on TOF source images. The primary outcome measure was the combined incidence of stroke, MI, and death within 30 days of CAS. Associations between IPH and the primary outcome were investigated. RESULTS: IPH was detected on TOF MRA in 30 patients. Symptomatic patients were more common in the IPH group than in the non-IPH group (66.7% vs 41.7%; P = .032). Overall, 30-day stroke, MI, or death rates were 6.6%. There was no significant difference in the primary outcome between the IPH and non-IPH groups (10% and 6.25%, respectively; hazard ratio for IPH, 1.151; 95% CI, 0.035 to 37.500; P = .937). A logistic regression showed there was no independent variable associated with the primary outcome. CONCLUSIONS: The results of this study indicate that protected CAS seems to be safe in patients with severe carotid stenosis and IPH.
BACKGROUND AND PURPOSE: Carotid IPH can be detected with MR imaging. The aim of this study was to determine the safety of CAS using an emboli protection device in patients with severe carotid artery stenosis and MR imaging-depicted carotid IPH. MATERIALS AND METHODS: We retrospectively reviewed a prospective data base that included 91 consecutive patients with severe carotid stenosis and high-risk features who were treated with CAS by using an emboli protection device. Seventy-eight of the included patients underwent prestenting 3D TOF MRA. IPH was defined as the presence of high signal intensity within the carotid plaque, greater than 150% of the signal intensity of the adjacent neck muscle on TOF source images. The primary outcome measure was the combined incidence of stroke, MI, and death within 30 days of CAS. Associations between IPH and the primary outcome were investigated. RESULTS:IPH was detected on TOF MRA in 30 patients. Symptomatic patients were more common in the IPH group than in the non-IPH group (66.7% vs 41.7%; P = .032). Overall, 30-day stroke, MI, or death rates were 6.6%. There was no significant difference in the primary outcome between the IPH and non-IPH groups (10% and 6.25%, respectively; hazard ratio for IPH, 1.151; 95% CI, 0.035 to 37.500; P = .937). A logistic regression showed there was no independent variable associated with the primary outcome. CONCLUSIONS: The results of this study indicate that protected CAS seems to be safe in patients with severe carotid stenosis and IPH.
Authors: Robert J Adams; Greg Albers; Mark J Alberts; Oscar Benavente; Karen Furie; Larry B Goldstein; Philip Gorelick; Jonathan Halperin; Robert Harbaugh; S Claiborne Johnston; Irene Katzan; Margaret Kelly-Hayes; Edgar J Kenton; Michael Marks; Ralph L Sacco; Lee H Schwamm Journal: Stroke Date: 2008-03-05 Impact factor: 7.914
Authors: Hideki Ota; Vasily L Yarnykh; Marina S Ferguson; Hunter R Underhill; J Kevin Demarco; David C Zhu; Minako Oikawa; Li Dong; Xihai Zhao; Alonso Collar; Thomas S Hatsukami; Chun Yuan Journal: Radiology Date: 2010-02 Impact factor: 11.105
Authors: B A N Verhoeven; J P P M de Vries; G Pasterkamp; R G A Ackerstaff; A H Schoneveld; E Velema; D P V de Kleijn; F L Moll Journal: Stroke Date: 2005-07-07 Impact factor: 7.914
Authors: Y Qiao; M Etesami; S Malhotra; B C Astor; R Virmani; F D Kolodgie; H H Trout; B A Wasserman Journal: AJNR Am J Neuroradiol Date: 2011-01-13 Impact factor: 3.825
Authors: Willem E Hellings; Wouter Peeters; Frans L Moll; Sebastiaan R D Piers; Jessica van Setten; Peter J Van der Spek; Jean-Paul P M de Vries; Kees A Seldenrijk; Peter C De Bruin; Aryan Vink; Evelyn Velema; Dominique P V de Kleijn; Gerard Pasterkamp Journal: Circulation Date: 2010-04-19 Impact factor: 29.690
Authors: Renu Virmani; Frank D Kolodgie; Allen P Burke; Aloke V Finn; Herman K Gold; Thomas N Tulenko; Steven P Wrenn; Jagat Narula Journal: Arterioscler Thromb Vasc Biol Date: 2005-07-21 Impact factor: 8.311
Authors: Frank D Kolodgie; Herman K Gold; Allen P Burke; David R Fowler; Howard S Kruth; Deena K Weber; Andrew Farb; L J Guerrero; Motoya Hayase; Robert Kutys; Jagat Narula; Aloke V Finn; Renu Virmani Journal: N Engl J Med Date: 2003-12-11 Impact factor: 91.245
Authors: H J M Barnett; D W Taylor; R B Haynes; D L Sackett; S J Peerless; G G Ferguson; A J Fox; R N Rankin; V C Hachinski; D O Wiebers; M Eliasziw Journal: N Engl J Med Date: 1991-08-15 Impact factor: 91.245
Authors: Nishath Altaf; Andrew Beech; Stephen D Goode; John R Gladman; Alan R Moody; Dorothee P Auer; Shane T MacSweeney Journal: J Vasc Surg Date: 2007-06-01 Impact factor: 4.268
Authors: Adam Mazurek; Krzysztof Malinowski; Kenneth Rosenfield; Laura Capoccia; Francesco Speziale; Gianmarco de Donato; Carlo Setacci; Christian Wissgott; Pasqualino Sirignano; Lukasz Tekieli; Andrey Karpenko; Waclaw Kuczmik; Eugenio Stabile; David Christopher Metzger; Max Amor; Adnan H Siddiqui; Antonio Micari; Piotr Pieniążek; Alberto Cremonesi; Joachim Schofer; Andrej Schmidt; Piotr Musialek Journal: J Clin Med Date: 2022-08-17 Impact factor: 4.964